Two Cases of Retroperitoneal Fibrosis During Anti-programmed Cell Death 1 Antibody Treatment-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Two Cases of Retroperitoneal Fibrosis During Anti-programmed Cell Death 1 Antibody Treatment

Published:2022-12-20 Issue:7 Volume:62 Page:1044-1047
ISSN:0386-9628
Container-title:Haigan
language:en
Short-container-title:JJLC

Author:

Fujiu Koichi¹,Utsumi Yu²,Omi Fumito³,Suzuki Motohisa⁴,Suzuki Hiroyuki⁵

Affiliation:

1. Department of General Thoracic Surgery, Southern TOHOKU General Hospital

2. Department of Respiratory Medicine, Hachinohe Red Cross Hospital

3. Department of Respiratory Medicine, Southern TOHOKU General Hospital

4. Department of Radiotherapy, Southern TOHOKU General Hospital

5. Department of Chest Surgery, Fukushima Medical University School of Medicine

Publisher

Japan Lung Cancer Society

Subject

Pulmonary and Respiratory Medicine,Oncology

Link

https://www.jstage.jst.go.jp/article/haigan/62/7/62_1044/_pdf

Reference10 articles.

1. 1. Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis. Lancet. 2006; 367: 241-251.

2. 2. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockage. N Engl J Med. 2018; 378: 158-168.

3. 3. Vaglio A, Maritati F. Idiopathic retroperitoneal fibrosis. J Am Soc Nephrol. 2016; 27: 1880-1889.

4. 4. Alberti C. Drug-induced retroperitoneal fibrosis: short aetiopathogenetic note, from the past times of ergot-derivatives large use to currently applied bio-pharmacology. G Chir. 2015; 36: 187-191.

5. 5. Couderc M, Mathieu S, Dubost JJ, Soubrier M. Retroperitoneal fibrosis during etanercept therapy for rheumatoid arthritis. J Rheumatol. 2013; 40: 1931-1933.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lower Urinary Tract Disorders as Adverse Drug Reactions—A Literature Review;Pharmaceuticals;2023-07-20

2. Nivolumab/pembrolizumab;Reactions Weekly;2023-02-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3